Literature DB >> 26796574

Decreased Monocyte HLA-DR Expression in Patients After Non-Shockable out-of-Hospital Cardiac Arrest.

Fabienne Venet1, Martin Cour, Julie Demaret, Guillaume Monneret, Laurent Argaud.   

Abstract

Out-of-hospital cardiac arrest (OHCA) constitutes a major health care problem with the development in immediate survivors of a post-cardiac arrest syndrome including systemic inflammatory response as observed in sepsis. As a decreased monocyte HLA-DR expression (mHLA-DR) has been repeatedly described in septic patients in association with an increased risk of death and nosocomial infections, we tested whether this immune alteration could also be observed after OHCA. Fifty-five non-shockable OHCA patients sampled at Day 0 (D0: within 4 h after OHCA), D1 (the next day), and D3: (after 2 additional days) were included. CD4+ lymphocyte count and mHLA-DR were evaluated by flow cytometry. We observed a marked decrease in mHLA-DR as early as D0 in patients compared with normal values. This decrease persisted till D3 and was associated with a moderate decrease in the number of circulating CD4+ lymphocytes. No correlations were identified between mHLA-DR and usual prognostic markers after OHCA. However, overtime evolution in mHLA-DR values appeared different between survivors and non-survivors with a quasisystematic decrease between D1 and D3 in non-survivors versus an increased expression in survivors. In conclusion, this preliminary pilot study describes the occurrence of OHCA-induced immune alterations as illustrated by a decreased mHLA-DR and CD4+ lymphopenia. Furthermore, we show for the first time the differential overtime evolution in mHLA-DR between survivors and non-survivors without association with usual prognostic markers and multiple organ failure. These initial results should now be confirmed in a larger cohort of OHCA patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26796574     DOI: 10.1097/SHK.0000000000000561

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

1.  Danger associated molecular patterns in injury: a double-edged sword?

Authors:  Guillaume Monneret; Fabienne Venet; Martin Cour; Laurent Argaud
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

2.  What's new in immunostimulating strategies in the ICU.

Authors:  Peter Pickkers; Tom van der Poll
Journal:  Intensive Care Med       Date:  2018-11-19       Impact factor: 17.440

3.  Lymphopaenia in cardiac arrest patients.

Authors:  Paola Villois; David Grimaldi; Savino Spadaro; Claudia Righy Shinotsuka; Vito Fontana; Sabino Scolletta; Federico Franchi; Jean-Louis Vincent; Jacques Creteur; Fabio Silvio Taccone
Journal:  Ann Intensive Care       Date:  2017-08-14       Impact factor: 6.925

Review 4.  Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers.

Authors:  Carmen Andrea Pfortmueller; Christian Meisel; Michaela Fux; Joerg C Schefold
Journal:  Intensive Care Med Exp       Date:  2017-10-23

5.  Number of Circulating CD 73-Expressing Lymphocytes Correlates With Survival After Cardiac Arrest.

Authors:  Sergey Ryzhov; Teresa May; John Dziodzio; Ivette F Emery; F L Lucas; Angela Leclerc; Barbara McCrum; Christine Lord; Ashley Eldridge; Michel P Robich; Fumito Ichinose; Douglas B Sawyer; Richard Riker; David B Seder
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

6.  Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series.

Authors:  Didier Payen; Valerie Faivre; Jordi Miatello; Jenneke Leentjens; Caren Brumpt; Pierre Tissières; Claire Dupuis; Peter Pickkers; Anne Claire Lukaszewicz
Journal:  BMC Infect Dis       Date:  2019-11-05       Impact factor: 3.090

7.  Effects of perioperative transcutaneous electrical acupoint stimulation on monocytic HLA-DR expression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass: study protocol for a double-blind randomized controlled trial.

Authors:  Wen-Ting Chen; Jin-Feng Wei; Lan Wang; Deng-Wen Zhang; Wei Tang; Jian Wang; Yue Yong; Jing Wang; Ya-Lan Zhou; Lan Yuan; Guo-Qiang Fu; Sheng Wang; Jian-Gang Song
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.